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ABSTRACT
Objective: Prevention of congenital heart disease (CHD) has been hampered by a lack of information about the known modifiable risk factors for 
abnormalities in cardiac development. Vitamin A plays an important role in the periods of rapid cellular growth and differentiation, especially during 
pregnancy. Assuming a link between Vitamin A levels and congenital malformations, hypothetical different levels of Vitamin A were evaluated in 
neonates with and without CHD, in this study.
Methods: In a case–control study that was conducted in 2015 in Mashhad/Iran, serum levels of Vitamin A in 30 neonates with CHD were compared 
to 30 healthy controls. The cases were diagnosed by echocardiography and recruited by convenience sampling. Demographic and laboratory data 
including age, sex, and serum Vitamin A level in each group were collected. Data analysis was done in SPSS V 20 software, and descriptive statistics, 
t-test, and analysis of covariance were used.
Results: The mean age in cases was 11±3.4 days and in controls was 12.5±4.8 days. A total of 18 patients (60%) were male. In CHD patients, 
10 cases (33.3%) had cyanotic heart disease, and 20 cases (66.7%) had non-cyanotic heart disease. The mean serum Vitamin A values in subjects 
(11.54±9.56 µg/dL) and controls (21.84±14.3 µg/dL) were significantly different, (p<0.05) and in case group was lower than the normal range.
Conclusion: There was a significant difference in serum Vitamin A values in subjects and controls. Therefore, awareness of people about the 
importance of this vitamin in preventing CHD in children seems necessary.
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INTRODUCTION
Congenital heart disease (CHD) is the general term used to describe any 
gross structural abnormality of the heart or intrathoracic great vessels 
at birth, which is potentially of functional significance [1]. Genetic 
or environmental causes may lead to faulty embryogenesis during 
gestational weeks 3–8. In this period of time, major cardiovascular 
structures begin to function, and finally give rise to CHD [2]. Although the 
reported birth prevalence of CHD varies widely among epidemiological 
studies, the estimate of 8 per 1,000 live births is generally accepted as 
the best approximation [2-6].
CHD is regarded as a significant health burden as it is one of the most 
common reasons for health services utilization among children with 
chronic conditions (accounting 1% of all pediatric hospitalization 
costs) [7]. Advances in diagnostic, surgical, interventional, and 
pharmacological approaches over the past decades have increased the 
survival of infants with CHD dramatically [3,8]. However, CHD is still 
the most frequent occurring congenital disorder [9] and the leading 
cause of infant deaths due to birth defects [7]. These patients suffer 
from the life-threatening associated complications such as pulmonary 
hypertension, endocarditis, arrhythmias, growth restriction, and 
repeated need for surgery [9-13].
The ability to reduce the mortality or morbidity of CHD is limited by 
the inadequate knowledge about its etiology. Only a small proportion 
(10–15%) of cases with CHD can be traced to known causes. These 
etiologies may include chromosomal aneuploidies, defects in single 
genes or known environmental factors (such as Maternal diabetes 
mellitus and phenylketonuria) [9]. Other environmental risk factors are 
complex and commonly have genetic-environmental interactions [14].
Retinoic acid (RA), an active form of Vitamin A, is one of the environmental 
factors that may affect the embryogenesis [9]. It plays essential roles 
in many physiological functions including vision, immunity, cell 
differentiation, epithelial integrity, red blood cell production, and 
reproduction [15,16]. Retinaldehyde dehydrogenases are essential for the 
generation of embryonic RA from Vitamin A. RA functions opposing CYP26 
members (which catabolize RA) and ligand-dependent nuclear receptors 
called RA receptors α, β, and γ and retinoid X receptors α, β, and γ [15,17].
Previous studies have been documented that Vitamin A may be teratogenic 
in humans when consumed in large doses during pregnancy. On the 
other hand, other studies suggested that Vitamin A deficiency (VAD) 
may also be considered as a clinical risk similar to excess retinoid [18]. 
Furthermore, it is found that antenatal Vitamin A supplementation 
decrease anemia, preterm delivery, deformity, intrauterine growth 
retardation, preeclampsia/eclampsia, low birth weight, poor infant 
growth, neonatal/infant, and maternal mortalities [16].
However, the precise role of RA in the development of CHD has not been 
clearly defined yet. This study is designed to evaluate the serum levels 
of Vitamin A in neonates with CHD, which may lead to a better insight 
into its etiology.
METHODS
In a case–control study, serum Vitamin A levels were measured in 
neonates with CHD and compared with the control group. Due to there 
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was not any similar study to our objective, we conducted this pilot study 
by recruiting 60 neonates in two groups.
The study was conducted in Mashhad during a 1-year period from April to 
March 2015 by convenience sampling method. The case group included 
30 children with CHD referred to a heart clinic of Azad University of 
Mashhad. Inclusion criteria in the case group included diagnosis of CHD 
by a pediatric cardiologist and through echocardiography, age of the 
child from birth to 30 days old, and parents’ consent for participation 
of their kids in the study. Exclusion criteria were low birth weight 
(<2500 g), any non-cardiac congenital disease, a known concurrent 
systemic disease, malnutrition, family history of heart disease, family 
history of congenital heart failure, and exposure to ionization radiation 
during pregnancy and familial marriage. Control group of 30 children 
was selected among children under the age of 1 month who were 
referred to health centers for routine childhood care by convenience 
sampling based on the same inclusion and exclusion criteria for the 
case group except having CHD. Roll out of CHD in control group was 
done by echocardiography similar to case group.
Demographic and laboratory data including age, sex, and serum Vitamin 
A level in each group were collected utilizing a checklist. In both case and 
control groups, 2 mL blood was taken from peripheral veins to separate 
the serum or plasma through centrifuge at 4°C, and frozen immediately 
in the plastic vials. The samples were kept away from the light in chilled 
tubes, and the serum level of Vitamin A was measured as µg/dL using 
HPLC liquid chromatography in one laboratory. Desired concentrations 
are approximately 20–60 µg/dL. Concentrations <20 µg/dL indicate 
deficiency [19].
The study has been approved by the University’s Institutional Review 
Board and ethical committee with the code number IR. Neyshabur. REC. 
1396. 11. The protocol was in accordance with the ethical principles 
of the Helsinki Declaration, and informed consent has been received 
from all parents and guardians of the study individuals. All costs of 
laboratory tests and traveling were covered by the researcher. All data 
and information remain confidential.
For analysis of the data, SPSS V 20 software was used. Descriptive 
statistics are presented for the study populations that result for 
continuous variables provided as means with SDs and results for 
categorical variables were provided as percentages. To compare the 
level of Vitamin A in both the case and control groups, first Kolmogorov–
Smirnov test was done, and then they were compared using t-test in two 
independent groups. Chi-square test was used to compare qualitative 
variables. The significance level <5% was considered for each test.
RESULTS
The mean age of the patients in the case and control groups was 11±3.4 
and 12.5±4.8 days, respectively, and the average age of their mothers 
was 30.21±17.34 and 28.42±15.73 in case and control group. We did 
not have a significant difference between the case and control group 
in the age of neonates (p=0.21) and their mothers (p=0.08). Gender 
distribution was similar in both case and control groups so that in both 
groups, 18 (60%) were boys and 12 (40%) girls. Among children in the 
case group, 10 (33.3%) and 20 (66.7%) had cyanotic and non-cyanotic 
heart diseases, respectively. The mean serum Vitamin A level in children 
with CHD was 11.54±9.56 µg/dL versus 21.84±14.3 µg/dL in control 
group; which the difference was statistically significant (p=0.005). This 
means that serum levels of this vitamin were lower in the patients’ 
group than in the control group.
Furthermore, the mean serum Vitamin A level in the patients with CHD 
was compared according to the type of heart disease (cyanotic versus 
non-cyanotic) (Table 1). As shown in Table 1, serum level of vitamin in 
children with and without cyanotic heart diseases is not significantly 
different (p>0.05).
DISCUSSION
In this study, the serum levels of Vitamin A showed a considerable 
decrease in children with CHD compared with normal and healthy 
children (without CHD) and this difference was significant.
In a similar study, mean levels of serum retinol in children with CHD 
in Nigeria showed no significant lower amounts than children without 
CHD; indicating no VAD in this disease. However, the mean serum retinol 
values were above the value for VAD in both the subjects and controls, 
addressing a possible adequate dietary source of Vitamin A in the case 
and control groups as Nigeria has a program in fortifying foods for the 
infants and the main source of this nutrient in older children and adult 
is palm oil [20]. Vieria et al. showed that the intake of calories, fats, fiber, 
sodium, potassium, and Vitamin A was below the recommended levels 
in children with congenital cardiopathy [21].
It has been demonstrated that Vitamin A may be crucial for heart 
morphogenesis during pregnancy, in terms of both its deficiency and 
excess. Vitamin A may play a specific role to promote heart development 
through activating some genes’ regulations in the gastrula stage [21]. 
In the 1950s, it was shown that maternal VAD in a rat model causes 
severe cardiac and great vessels anomalies during embryogenesis. 
Furthermore, caused hypervitaminosis A (by active form of RA) has 
been one of the earliest teratogenic models of heart defects [22]. In 
other studies, different models have been developed to address the role 
of RA during early development. Among them, the Vitamin A - deficient 
quail was proposed as an ideal model for the Vitamin A functional 
studies in the vertebrate embryo. More recently, the discovery of 
retinoid synthesis of biochemical pathways and retinoid receptors has 
allowed some genetic manipulations including in mouse embryos for 
deciphering RA function [23]. The retinoid-binding protein/STRA6 
system of VAD is the only possible mechanism for cells or tissues to 
obtain Vitamin A and the major transport form of it in the blood. STRA6 
is a membrane receptor mediates cellular uptake of retinol, and its 
alteration cause CHD as well as anophthalmia, mental retardation, and 
embryonic lethality, demonstrating the critical function of Vitamin A in 
the pathogenesis of CHD [24].
In the field of human studies, Botto et al. reported that women who 
used multivitamin supplements in the periconceptional period were at 
significantly lower risk of having babies with some CHDs (specifically outflow 
tract and VSD) than women who not used. The timing of multivitamin use 
seem to be critical, as the apparent risk reduction is evident for the time 
of conception or early in the 1st month but not later in the pregnancy [25].
CONCLUSIONS
Considering the results of this study and lower serum Vitamin A levels 
in children with CHD, awareness of people about the importance of this 
vitamin in preventing CHD in children seems necessary. Furthermore, 
family members of these children should receive counseling on how 
Table 1: Distribution of serum Vitamin A levels in affected children by type of CHD
CHD No Mean+SD Median Range Statistic p value
Max Min
Cyanotic 7 6.08±4.9 3.47 1.66 13.05 t=−1.38 0.184
Non-cyanotic 13 14.67±11.88 9.41 1.97 60.89
CHD: Congenital heart disease
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to supplement the calories, vitamins, and minerals required when 
there are deficiencies that cannot be corrected through natural oral 
feeding, so as not to limit the synthesis necessary for the growth and 
development of these children.
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